Rifampicin-monoresistant Mycobacterium tuberculosis among the patients visiting chest clinic, state specialist hospital, Akure, Nigeria

Lateef A. Bello, Mujeeb O. Shittu, Bashirat T. Shittu, Adeolu S. Oluremi, Oluwagbenga N. Akinnuroju, Saheed A. Adekola


Background:Tuberculosis (TB), one of the most important contagious diseases, is a leading cause of death due to a single pathogen worldwide. Co-infection of people living with HIV with M. tuberculosis has been shown to increase the mortality rate in sub-Saharan Africa.

Methods:This present study was carried out to establish the rifampicin resistant profiles among the patients attending chest clinic, state specialist hospital, Akure. We enrolled clinical samples submitted between January 2013 and December 2013 for this study. The sputum samples were analyzed using GeneXpert.

Results:Of the 135 sputum processed by GeneXpert, 48 (35.6%) contained Mycobacteria tuberculosis (MTB) and 9 (18.8%) were rifampicin resistant Mycobacteria tuberculosis. Patients within the age group of 24-32 years showed the highest resistant to RIF 6 (12.5%).

Conclusion:This study has helped to establish that there is presence of rifampicin resistant Mycobacterium tuberculosis in Akure, Ondo state, Nigeria and most of them were observed among patients who default treatment. This is considered as a threat to TB control programme in Akure, Nigeria and it is recommended that strategies should be put in place in order to ensure patients’ compliance and monitoring of patients’ response to TB treatment.



Rifampicin resistant, Mycobacterium tuberculosis, GeneXpert, Akure

Full Text:



Van Gorkom J, Kibuga D, Adallah S, Adungosi J, Aluvaala B, Kangangi J, et al. HIV-sero-prevalence among tuberculosis patients in Kenya. East Afr Med J. 1999;76:452-6.

Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009-21.

WHO. Global tuberculosis control: surveillance, planning, financing, 2008. Available at: http://www.who.int/tb/publications/global_report/2008/en/.

Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA. 2005;293:2767-75.

Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. 2001;104:901-12.

Kan M. Current status of tuberculosis in Taiwan. Epidemiol Bull Cent Dis Control Dep Health ROC. 2000;16:44-7.

Crofton J, Mitchison D. Streptomycin resistance in pulmonary tuberculosis. Br Med J. 1948;2:1009-15.

Espinal MA. The global situation of MDR-TB. Tuberc Edinb. 2003;83:44-51.

Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992;326:1514-21.

Fischl MA, Uttamchandani RB, Daikos GL, Poblete RB, Moreno JN, Reyes RR, et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med. 1992;117:177-83.

Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. International union against tuberculosis and lung disease. Clin Infect Dis. 1997;24(1):S121-30.

Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. In: Hatful GF, Jacobs WR Jr, eds. Molecular Genetics of Mycobacteria. Washington DC: ASM Press; 2000: 235-254.

Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis. 1986;133:423-30.

Nwadioha SI, Nwokedi EO, Ezema GC, Eronini NC, Anikwe A, Audu F, et al. Drug resistant Mycobacterium tuberculosis in Benue, Nigeria. Br Microbiol Res J. 2014;4(9):989-95.

Michael F, Robert E, Regina S, Helga L, Ingo BA, Volkhard AJK, et al. Evaluation of Mycobacterium tuberculosis drug susceptibility in clinical specimens from Nigeria using genotype mtbdrplus and mtbdrsl assays. Eur J Microbiol Immunol. 2013;3(4):252-7.

Fawcet IW, Watkins BJ. Initial resistance of Mycobacterium tuberculosis in Northern Nigeria. Tubercle. 1976;57:71-3.

Sandgren A, Hollo V, Huitric E, Kodmon C. Epidemiology of tuberculosis in the EU/EEA in 2010: monitoring the progress towards tuberculosis elimination. Euro Surveill. 2012 Mar;17(12). pii: 20124.

Lawson L, Habib AG, Okobi MI, Idiong D, Olajide I, Emenyonu N, et al. Pilot study on multidrug resistant tuberculosis in Nigeria. Ann Afr Med. 2010;9(3):184-7.

Dinic L, Akande P, Idigbe EO, Ani A, Onwujekwe D, Agbaji O, et al. Genetic determinants of drug-resistant tuberculosis among HIV-infected patients in Nigeria. J Clin Microbiol. 2012 Sep;50(9):2905-9.

Akaninyene O, Victor U, Abdulrazak H, Soter A, Lawson L, Victor A. Clinical study of drug resistance among pulmonary tuberculosis patients in Calabar, Nigeria. Pulm Med. 2013;10:10-6.

World Health Organization. Global tuberculosis control. In: WHO, eds. WHO Report. Geneva, Switzerland: WHO; 2011: 3-246.

World Health Organization (Regional Office for Africa). WHO Nigeria support for rapid scaling-up of programmatic management of drug resistant tuberculosis in Nigeria, 2012. Available at: http://www.afro.who.int/en/nigeria/press-materials/item/4393-who-nigeria-support-for-rapid-scaling-up-of-programmatic-management-of-drug-resistant-tubercloisis-in-nigeria.html.

Olusoji D, Elutayo O, Olanrewaju O, Olapade GD. Pre-extensive drug resistant TB among MDR-TB patients. Global Advd Res J Microbiol. 2013;2(2):22-5.